SOURCE: SpectraScience, Inc.

May 19, 2015 09:15 ET

SpectraScience Technology Demonstrates Efficacy in Bladder Lesions

SAN DIEGO, CA--(Marketwired - May 19, 2015) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today a recently published scientific paper indicated that light-based technology could be useful in diagnosing cancerous bladder lesions. The paper was published in the March 2015 edition of the Journal of Photodiagnosis and Photodynamic Therapy. The published data showed sufficient statistical differences in the measurement of benign and cancerous tissue to suggest it could reduce the rate of false positive bladder biopsies and reduce unnecessary medical procedures. SpectraScience supplied the instrument that was used in conducting the research summarized in the scientific paper.

"We are pleased to see the excellent results obtained by the study team. Their analysis showed not only differences between benign and malignant tissue, but also a distinction between superficial and deep malignant tissue," stated Michael Oliver, President and Chief Executive Officer. "This just provides additional justification to our belief that our platform technology has applicability in a variety of organ systems. A key component of our long-range strategy has always been developing additional products to diagnose a variety of cancers. Results like these simply reinforce the value of our technology and the validity of our approach." 

About SpectraScience, Inc.:

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.

For more information:

Visit our web site

Forward-Looking Statement for SpectraScience, Inc.

This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

Contact Information

  • Contacts:
    Media and Investors:
    SpectraScience, Inc.
    Lowell Giffhorn
    Phone: (858) 847-0200 x2019
    Email: Email Contact